Utilization and perspectives of weight loss medications in pediatric metabolic dysfunction‐associated steatotic liver disease

Ähnliche Einträge

• Pharmacological management of pediatric metabolic dysfunction‐associated steatotic liver disease
  von: Rasha Abi Radi Abou Jaoudeh, et al.
  Veröffentlicht: (2024)
• Vibration‐controlled transient elastography in pediatric metabolic dysfunction‐associated steatotic liver disease
  von: Lauren B. Nichols, et al.
  Veröffentlicht: (2025)
• FISPGHAN statement on the global public health impact of metabolic dysfunction‐associated steatotic liver disease
  von: Tania Mitsinikos, et al.
  Veröffentlicht: (2024)
• Ability of triglyceride‐glucose indices to predict metabolic dysfunction associated with steatotic liver disease in pediatric obesity
  von: Procolo Di Bonito, et al.
  Veröffentlicht: (2025)
• Glucagon‐like peptide‐1 receptor agonists in pediatric metabolic dysfunction‐associated steatotic liver disease
  von: Andrea M. Tou, et al.
  Veröffentlicht: (2025)